Activation of C-X-C motif chemokine receptor 4 (CXCR4) has been reported to result in lung protective effects in various experimental models. The effects of pharmacological CXCR4 modulation on the development of acute respiratory distress syndrome (ARDS) after lung injury, however, are unknown. Thus, we studied whether blockade and activation of CXCR4 influences development of ARDS in a unilateral lung ischaemia-reperfusion injury rat model. Anaesthetized, mechanically ventilated animals underwent right lung ischaemia (series 1, 30 minutes; series 2, 60 minutes) followed by reperfusion for 300 minutes. In series 1, animals were treated with vehicle or 0.7 μmol/kg of AMD3100 (CXCR4 antagonist) and in series 2 with vehicle, 0.7 or 3.5 μmol/kg ubiquitin (non-cognate CXCR4 agonist) within 5 minutes of reperfusion. AMD3100 significantly reduced PaO 2 /FiO 2 ratios, converted mild ARDS with vehicle treatment into moderate ARDS (PaO 2 /FiO 2 ratio<200) and increased histological lung injury. Ubiquitin dose-dependently increased PaO 2 /FiO 2 ratios, converted moderateto-severe into mild-to-moderate ARDS and reduced protein content of bronchoalveolar lavage fluid (BALF). Measurements of cytokine levels (TNFα, IL-6, IL-10) in lung homogenates and BALF showed that AMD3100 reduced IL-10 levels in homogenates from post-ischaemic lungs, whereas ubiquitin dose-dependently increased IL-10 levels in BALF from post-ischaemic lungs. Our findings establish a cause-effect relationship for the effects of pharmacological CXCR4 modulation on the development of ARDS after lung ischaemia-reperfusion injury. These data further suggest CXCR4 as a new drug target to reduce the incidence and attenuate the severity of ARDS after lung injury.
increased pulmonary capillary permeability, third spacing of fluids into the lung and formation of lung oedema, the hallmark of ARDS. 9, 10 While several independent risk factors for development of ARDS have been identified, such as pneumonia, non-pulmonary-sepsis or severe injuries, the molecular events leading to ARDS remain poorly understood. 4, 9, 11, 12 Thus, therapeutic options are currently limited to lung-protective ventilation strategies. 5, 6, 13 Pharmacological interventions that may attenuate progression of mild ARDS to moderate or severe ARDS are currently not available, but urgently needed.
The G protein-coupled receptor C-X-C motif chemokine receptor 4 (CXCR4) is abundantly expressed in tissues, including lung epithelial and vascular endothelial cells. 14, 15 CXCR4 is essential during embryonic development, has pleiotropic roles in the immune system, during tissue repair [16] [17] [18] [19] and gained particular attention as a drug target through its role in cancer metastases and HIV infection.
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More recently, it has been reported that administration of the cognate CXCR4 agonist CXCL12 (stromal cell-derived factor-1α) and of the non-cognate CXCR4 agonist ubiquitin result in lung protective effects in various experimental models. [23] [24] [25] [26] [27] [28] While these data suggest CXCR4 as a potential therapeutic target to attenuate lung injury, the effects of pharmacological activation and blockade of CXCR4 on the development of ARDS after lung injury have not been systematically studied. Such data, however, are essential prerequisites to establish CXCR4 as a possible new drug target. Thus, in the present study we tested how blockade of endogenous CXCR4 with the selective CXCR4
antagonist AMD3100 and activation of CXCR4 with the non-cognate CXCR4 agonist ubiquitin modulate development and severity of ARDS in a unilateral lung warm ischaemia-reperfusion injury rat model.
| RESULTS

| Effects of AMD3100 after lung ischaemiareperfusion injury
In the first series of experiments, we tested the effects of the selective CXCR4 antagonist AMD3100 on the development of ARDS after unilateral lung ischaemia-reperfusion injury. There were no significant differences for any physiological parameter between animals treated with vehicle and AMD3100 at baseline. Mean arterial blood pressures (MAP; Figure 1A ), blood lactate concentrations ( Figure 1B ), creatinine concentrations ( Figure 1B ) and hematocrit values ( Figure 1C) were comparable between vehicle-and AMD3100-treated animals throughout the observation period. As compared with vehicle-treated animals, leukocyte counts in AMD3100-treated animals were significantly increased at the end of the experiment ( Figure 1D ). While peak inspiratory pressures required to maintain minute volumes were indistinguishable between the groups ( Figure 1E ,F), there were significant differences in PaO 2 /FiO 2 (P/F)-ratios between animals with vehicle and AMD3100 treatment ( Figure 1G ). In vehicle-treated animals P/F ratios decreased from 546 ± 18 mmHg at baseline to 299 ± 12 mmHg at t = 300 minutes. With AMD3100-treatment, P/F ratios were significantly lower at t = 60 minutes and remained significantly reduced until the end of the experiment, as compared with vehicle-treated animals. With AMD3100 treatment, animals fulfilled criteria for mild ARDS (P/F ratio < 300 mmHg) at t = 60 minutes and criteria for moderate ARDS (P/F ration < 200 mmHg) at t = 240 minutes. (11/27); AMD3100, 7 (6/10), P = .031).
| Effects of ubiquitin after lung ischaemiareperfusion injury
In the second series of experiments, we tested the effects of the noncognate CXCR4 agonist ubiquitin. To be able to assess whether activation of CXCR4 with ubiquitin could attenuate ARDS development after lung ischaemia-reperfusion injury, we increased the ischaemic F I G U R E 1 AMD3100 treatment promotes development of ARDS after lung ischaemia-reperfusion injury. Animals underwent lung ischaemia for 30 minutes, followed by reperfusion until t = 300 minutes. Arrows indicate the time point of drug injection. Open symbols: vehicle treatment (n = 5). The P:F ratios of the animals are shown in Figure 4G . With vehicle treatment, P:F ratios decreased continuously to 111 ± 10 mmHg at t = 300 minutes. Vehicle-treated animals fulfilled criteria for mild ARDS (P:F ratio < 300 mmHg) at t = 90 minutes and criteria for moderate ARDS (P:F ratio < 200 mmHg) at t = 180 minutes.
With 0.7 μmol/kg ubiquitin, P:F ratios were significantly higher until 
| DISCUSSION
In the present study, we tested how pharmacological modulation of CXCR4 influences the development of ARDS after unilateral lung ischaemia-reperfusion injury. Our findings suggest that blockade of While there is no single animal model that is able to resemble all aspects of the human pathophysiology, lung ischaemia reperfusion injury is a well-accepted model that reflects key features of human ARDS. 29, 30 The current Berlin definition of ARDS grades the severity of ARDS based on the P/F ratio under positive end expiratory pressure (PEEP) or continuous positive airway pressure of equal or >5 cmH 2 O (mild, 200 < P/F < 300 mmHg; moderate, 100 < P/F < 200 mmHg; severe, P/F < 100 mmHg). 8 Thus, we ventilated animals with a PEEP of 5 cmH 2 O during the reperfusion period to be able to monitor the temporal pattern of ARDS development in our model. In series 1, control animals barely reached the criteria for mild ARDS at the end of the observation period. In contrast, AMD3100 treatment shortly after reperfusion accelerated development of ARDS and increased the severity of the reperfusion injury to moderate ARDS. In combination with the observation of increased histological lung injury with AMD3100 treatment, these findings imply that endogenous CXCR4 mediates lung protective effects in the pathophysiology of ARDS. Furthermore, our finding that AMD3100 treatment promotes ARDS development is in agreement with previous reports that CXCR4 blockade increases mortality and tissue injury in models of endotoxemia and polymicrobial sepsis, and that administration of AMD3100 impairs hemodynamic stability in models of traumatic-haemorrhagic shock. [31] [32] [33] [34] [35] [36] Collectively, these data indicate that endogenous CXCR4 plays important roles in infectious and non-infectious inflammation, and provides tissue/ organ protection, including lung protection. The observation that leukocyte counts at the end of the observation period were significantly higher with AMD3100 treatment, as compared with vehicle treatment, is in line with its known pharmacological properties. 32, 37 In contrast to AMD3100 treatment, ubiquitin treatment dosedependently increased P/F ratios and converted moderate-to-severe ARDS into mild-to-moderate ARDS. Although we were unable to differentiate the degree of histological lung injury between vehicle-and ubiquitin-treated animals, measurements of BAL fluid protein content showed that protein leakage into the alveolar space was significantly reduced with ubiquitin treatment. As this effect was detectable in BAL fluid from the post-ischaemic lung and from the contralateral lung, these findings suggest that CXCR4 activation stabilizes permeability of the alveolar-capillary membrane, through which it reduces direct and remote lung injury, respectively. This assumption is supported by previous observations suggesting enhanced pro-inflammatory responses after pharmacological CXCR4
blockade and enhanced anti-inflammatory responses following CXCR4 activation. 23, 31, 32, 41 As CXCR4 has been reported to regulate vascular endothelial barrier function, direct effects of pharmacological CXCR4 modulators on pulmonary vascular permeability, independent of the cytokine network, may also account for the observed effects. 45 To delineate the exact underlying mechanisms and target cell populations, detailed mechanistic studies will be required. Such studies, however, are beyond the scope of the present study. In conclusion, the present study confirms previous reports suggesting therapeutic potential of CXCR4 agonists to attenuate lung injury in various animal models, establishes cause-effect relationships for the effects of pharmacological CXCR4 modulation on the development of ARDS after lung ischaemia-reperfusion injury and provides initial pre-clinical evidence that CXCR4 agonists could be used to attenuate progression of mild ARDS to moderate and severe ARDS. Our findings point towards CXCR4 as a drug target to reduce the incidence and attenuate the severity of ARDS. Future studies delineating the molecular mechanisms underlying the protective effects of CXCR4 activation as well as pre-clinical efficacy studies in other ARDS models will be required to characterize and better understand the translational potential of this new therapeutic approach.
| METHODS
| Lung ischaemia-reperfusion injury model
All At t = 300 minutes, animals were killed (5% isoflurane, bilateral pneumothorax) and both lungs harvested for histology and measurements of inflammatory markers in whole lung homogenates.
All experiments were performed randomized and blinded. Animals received vehicle (0.5 mL NS, n = 5) or AMD3100 (700 nmol/kg, n = 5) in 0.5 mL NS intra-arterially within 5 minutes of reperfusion after a 30 minute period of ischaemia. Animals received vehicle (0.5 mL NS, n = 6), 0.7 μmol/kg ubiquitin (n = 6) or 3.5 μmol/ kg ubiquitin (n = 5) intra-arterially within 5 minutes of reperfusion following a 60 minute period of ischaemia. Dosing of AMD3100
and ubiquitin was selected based on our previous studies in other animal models.
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| Bronchoalveolar lavage
At the completion of the 60 minutes ischaemia groups (t = 300 min- 
| Arterial blood gases and routine laboratory parameters
Arterial blood gases, electrolytes, creatinine, lactate, hematocrit and hemoglobin were analyzed using the Element point of care veterinary blood gas, electrolyte and critical care analyzer (Cuattro Veterinary USA, Loveland, CO, USA). Complete blood counts were analyzed using the Hematrue hematology analyzer (Cuattro Veterinary USA).
| Histopathological analysis of lung tissue
For histomorphological examination, lung specimens were placed in formalin fixative solution and sent to AML Labs (Saint Augustine, FL, USA), where they were embedded in paraffin wax, sliced into 5 μm sections and stained with H&E. From each lung specimen, six slides were prepared. The slides were examined under a light microscope by three investigators who were blinded as to the identity of the specimens. Histopathology was assessed using a previously described LIS, with slight modifications. 47 In brief, each investigator rendered a score of 0 (no damage) to 4 (maximal damage) based on the following criteria: (i) alveolar congestion; (ii) presence of haemorrhage; (iii) interstitial oedema; and (iv) alveolar wall thickness.
| Lung wet weight to dry weight ratios
The ratio of the tissue wet weight to dry weight (W/D) was determined gravimetrically, as previously described.
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| Lung extract preparation
Snap frozen tissues were homogenized in 1/10 phosphate buffered saline, pH 7.4 (1:5 weight/volume), centrifuged (20 000 g, 4°C,
30 minutes) and supernatants (=extracts) aliquoted, as described. 
| Myeloperoxidase (MPO)
Myeloperoxidase was measured in lung extracts using a commercially available assay kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. 
| Lipid peroxidation assay
